LoQus23 Therapeutics key facts
- Developer of allosteric small molecule inhibitors targeting MSH3/MutSbeta designed to treat Huntington's disease and other triplet repeat neurodegenerative disorders.
- LoQus23 Therapeutics’s last known valuation is $61.4M.
- It has raised $67.2M; the latest was Later Stage VC ($46.3M) in Oct 2024.
- Notable investors include SV Health Investors, Forbion, Novartis Venture Fund.
- Status: Privately Held (backing).
Who backs LoQus23 Therapeutics
3- ·Watch LoQus23 Therapeutics: the Monday email on marks, rounds and moves
LoQus23 Therapeutics funding rounds
No funding rounds for LoQus23 Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
LoQus23 Therapeutics valuation
LoQus23 Therapeutics's last known valuation is $61.4 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
LoQus23 Therapeutics investors
3 investors are on record for LoQus23 Therapeutics, including SV Health Investors, Forbion and Novartis Venture Fund.
About LoQus23 Therapeutics
Developer of allosteric small molecule inhibitors targeting MSH3/MutSbeta designed to treat Huntington's disease and other triplet repeat neurodegenerative disorders. The company's therapeutics modulate the DNA mismatch repair pathway to address the underlying genetic mechanisms of these conditions, enabling the development of disease-modifying treatments for patients with repeat expansion-driven neurodegeneration.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2019
- Employees
- 9
- Website
- loqus23.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
LoQus23 Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.